Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Economic Evaluation of Ramosetron in Male Patients with Diarrhea-predominant Irritable Bowel Syndrome in Korea

설사형 과민성 장 증후군 남성 환자에게 사용되는 ramosetron 의 경제성 평가

  • Sohn, Hyun-Soon (College of Pharmacy, Sookmyung Women's University) ;
  • Lee, Tae-Jin (School of Public Health, Seoul National University) ;
  • Kim, Sun (School of Public Health, Seoul National University)
  • 손현순 (숙명여자대학교 약학대학) ;
  • 이태진 (서울대학교 보건대학원) ;
  • 김선 (서울대학교 보건대학원)
  • Received : 2010.09.27
  • Accepted : 2010.11.11
  • Published : 2010.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

This study was conducted to analyze the cost-utility of ramosetron monotherapy, trimebutine monotherapy and trimebutine+loperamide combination therapy in male diarrhea-predominant patients with irritable bowel syndrome (IBS) in Korean healthcare setting. We constructed a decision-analytical model to estimate both total costs for each state of health and outcomes such as IBS-symptoms improvement for 3 and 6 months time horizon. Base analysis found that for ramosetron treatment with the price of KW910 for 5 ${\mu}g$ tablet, incremental cost effectiveness ratios (ICERs, cost per quality-adjusted life day) were KW85,000 and KW62,000 for 3 months and 6 months, respectively, compared with trimebutine. But ramosetron was a dominant strategy when compared with trimebutine+loperamide for both 3 months and 6 months. Sensitivity analyses showed robust results for drug acquisition costs till ramosetron price of KW950/tablet. In conclusion, ramosetron was a cost-effective regimen compared with trimebutine or trimebutine+loperamide from the societal perspective.

Keywords

References

  1. Kang JY. Systematic review: the influence of geography and ethnicity in irritable bowel syndrome. Aliment Pharmacol Ther. 2005; 21(6): 663-76. https://doi.org/10.1111/j.1365-2036.2005.02396.x
  2. International Statistical Classification of Diseases and Related Health Problems 10th Revision, Available at http://apps.who.int/classifications/apps/icd/icd10online/. Accessed June 20, 2009.
  3. Rome foundation, Rome criteria, Available at http://www.romecriteria.org/. Accessed October 23, 2009.
  4. Choi H, Choi MG, Kim SW, et al., Functional gastrointestinal disorders in patients with gastrointestinal symptoms. Korean J Gastroenterol 1999; 33: 741-48.
  5. Han SH, Lee OY, Bae SC, et al., Prevalence of irritable bowel syndrome in Korea: population-based survey using the Rome II criteria. J Gastroenterol Hepatol. Nov 2006; 21(11): 1687-92. https://doi.org/10.1111/j.1440-1746.2006.04269.x
  6. Park KS, Ahn SH, Hwang JS, et al., A survey about irritable bowel syndrome in South Korea: prevalence and observable organic abnormalities in IBS patients. Dig Dis Sci. 2008; 53(3): 704-11. https://doi.org/10.1007/s10620-007-9930-1
  7. 한국보건의료연구원. 연구성과. Available at http://ktic.neca.re.kr/ktic/publication/disease_view.jsp?t=20100729203421952&runMode=boardView&seq=30&boardNo=GB&menuName=%C1%F8%C7%E0%C1%DF%C0%CE+%BF%AC%B1%B8&named=%C1%F8%C7%E0%C1%DF%C0%CE+%BF%AC%B1%B8. Accessed July 28, 2010.
  8. Fauci AS, Braunwald E, Kasper DL, et al., Harrison's Online Featuring the complete contents of Harrison's Principles of Internal Medicine, 17e.
  9. Agrawal A, Whorwell PJ, Irritable bowel syndrome: diagnosis and management, BMJ 2006; 332: 280-83. https://doi.org/10.1136/bmj.332.7536.280
  10. 건강보험심사평가원. 2008년 진료비 통계지표. Available at http://www.hira.or.kr/common/dummy.jsp?pgmid=HIRAF010303000000, Accessed October 16, 2009.
  11. National Institute for Health and Clinical Excellence (NICE). Irritable bowel syndrome in adult. Diagnosis and management of irritable bowel syndrome in adults in primary care. London. 2008.
  12. Park HJ. Evidence based guideline for diagnosis and treatment: therapeutic guideline for irritable bowel syndrome. Korean J Neurogastroenterol Motil 2005;11:36-43.
  13. 의약품안전청. 의약품 정보. Available at http://ezdrug.kfda.go.kr/kfda2. Accessed October 23, 2009.
  14. Matsueda K, Harasawa S, Hongo M, et al., A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008; 77(3-4): 225-35. https://doi.org/10.1159/000150632
  15. Pharmaxogilvy Healthworld. IBS Market Understanding Study Report. 2009. 6. 29.
  16. IMS data MAT 06/2009.
  17. Matsueda K, Harasawa S, Hongo M, et al., A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol, 2008; 43(10): 1202-11. https://doi.org/10.1080/00365520802240255
  18. Fielding JF, Double blind trial of trimebutine in the irritable bowel syndrome. Ir Med J, 1980; 73(10): 377-79.
  19. Astellas Report. YM060 - 장기투여시험 총괄보고서(Protocol No. 060-CL-203). 2006. 8. 23.
  20. Brennan S, Lucinda H, Susan L, et al., Developing valid and reliable health utilities in irritable bowel syndrome: Results from the IBS PROOF cohort. Am J Gastroenterol. 2009; 104(8): 1984-91. https://doi.org/10.1038/ajg.2009.232
  21. 건강보험심사평가원. 의약품 주성분별 가중평균가격. 2009 상반기.
  22. 건강보험심사평가원. 건강보험요양급여비용. 2009.
  23. 보건복지부.한국보건사회연구원.국민건강영양조사 (2005). 2006. 7.
  24. 국가통계포털, 통계청. 소비자물가지수. Available at http://kosis.kr/nsportal/abroad/abroad_01List.jsp?parentId=C. Accessed October 16, 2010.
  25. Akehurst RL, Brazier JE, Mathers N, et al., Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics. 2002; 20(7): 455-62. https://doi.org/10.2165/00019053-200220070-00003
  26. Brun-Strang C, Dapoigny M, Lafuma A, et al., Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study. Eur J Gastroenterol Hepatol. 2007; 19(12): 1097-103. https://doi.org/10.1097/MEG.0b013e3282f1621b